XRP2.F Silence Therapeutics PLC R | US82686Q1013
Financials
Trends
Details
| Breakdown | 31.12.2027 | 31.12.2026 | Change % |
|---|---|---|---|
| Total Revenue | 3.442.750 | 2.496.570 | 37.90% |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| Operating Expense | -- | -- | -- |
| Selling General and Administrative | -- | -- | -- |
| Research & Development | -- | -- | -- |
| Operating Income | -- | -- | -- |
| Pretax Income | -- | -- | -- |
| Net Income Common Stockholders | -- | -- | -- |
| Basic EPS | -- | -- | -- |
| Diluted EPS | -- | -- | -- |
| Analyst Count | 6 | 7 | 14.29% |
| EBIT | -- | -- | -- |
| EBITDA | -- | -- | -- |